WEKO3
アイテム
Phospho-Smad3 signaling is predictive biomarker for hepatocellular carcinoma risk assessment in primary biliary cholangitis patients.
https://kmu.repo.nii.ac.jp/records/206
https://kmu.repo.nii.ac.jp/records/2065abcbfbd-85bf-4857-986c-d3211f5817a7
| 名前 / ファイル | ライセンス | アクション |
|---|---|---|
論文要旨（要約） (184.5 kB)
|
||
|
審査結果要旨 (107.4 kB)
|
| Item type | 学位論文 / Thesis or Dissertation(1) | |||||
|---|---|---|---|---|---|---|
| 公開日 | 2022-12-16 | |||||
| タイトル | ||||||
| タイトル | Phospho-Smad3 signaling is predictive biomarker for hepatocellular carcinoma risk assessment in primary biliary cholangitis patients. | |||||
| 言語 | en | |||||
| タイトル | ||||||
| タイトル | Phospho-Smad3 signaling is predictive biomarker for hepatocellular carcinoma risk assessment in primary biliary cholangitis patients. | |||||
| 言語 | en | |||||
| 言語 | ||||||
| 言語 | eng | |||||
| キーワード | ||||||
| 言語 | en | |||||
| 主題Scheme | Other | |||||
| 主題 | Biomarkers | |||||
| キーワード | ||||||
| 言語 | en | |||||
| 主題Scheme | Other | |||||
| 主題 | Carcinoma, Hepatocellular | |||||
| キーワード | ||||||
| 言語 | en | |||||
| 主題Scheme | Other | |||||
| 主題 | Hepatitis C, Chronic | |||||
| キーワード | ||||||
| 言語 | en | |||||
| 主題Scheme | Other | |||||
| 主題 | Humans | |||||
| キーワード | ||||||
| 言語 | en | |||||
| 主題Scheme | Other | |||||
| 主題 | Liver Cirrhosis, Biliary | |||||
| キーワード | ||||||
| 言語 | en | |||||
| 主題Scheme | Other | |||||
| 主題 | Liver Neoplasms | |||||
| キーワード | ||||||
| 言語 | en | |||||
| 主題Scheme | Other | |||||
| 主題 | Risk Assessment | |||||
| キーワード | ||||||
| 言語 | en | |||||
| 主題Scheme | Other | |||||
| 主題 | Signal Transduction | |||||
| キーワード | ||||||
| 言語 | en | |||||
| 主題Scheme | Other | |||||
| 主題 | Smad3 Protein | |||||
| キーワード | ||||||
| 言語 | en | |||||
| 主題Scheme | Other | |||||
| 主題 | Transforming Growth Factor beta | |||||
| 資源タイプ | ||||||
| 資源タイプ識別子 | http://purl.org/coar/resource_type/c_46ec | |||||
| 資源タイプ | thesis | |||||
| 別タイトル | ||||||
| その他のタイトル | 原発性胆汁性胆管炎＜PBC＞発癌におけるバイオマーカーとしてのSmad3リン酸化の有用性の検討 | |||||
| 著者 |
中村, 尚広
× 中村, 尚広× Nakamura, Naohiro× Yoshida, Katsunori× Tsuda, Rinako× Murata, Miki× Yamaguchi, Takashi× Suwa, Kanehiko× Ichimura, Mayuko× Tsuneyama, Koichi× Matsuzaki, Koichi× Nakano, Toshiaki× Hirohara, Junko× Seki, Toshihito× Okazaki, Kazuichi× Gershwin, M Eric× Naganuma, Makoto |
|||||
| 抄録 | ||||||
| 内容記述タイプ | Abstract | |||||
| 内容記述 | Patients with primary biliary cholangitis (PBC) are at increased risk for development of hepatocellular carcinoma (HCC), particularly in the presence of comorbidities such as excessive alcohol consumption. Although liver fibrosis is an important risk factor for HCC development, earlier predictors of future HCC development in livers with little fibrosis are needed but not well defined. The transforming growth factor (TGF)-β/Smad signaling pathway participates importantly in hepatic carcinogenesis. Phosphorylated forms (phospho-isoforms) in Smad-related pathways can transmit opposing signals: cytostatic C-terminally-phosphorylated Smad3 (pSmad3C) and carcinogenic linker-phosphorylated Smad3 (pSmad3L) signals. | |||||
| 抄録 | ||||||
| 内容記述タイプ | Abstract | |||||
| 内容記述 | To assess the balance between Smad signals as a biomarker of risk, we immunohistochemically compared Smad domain-specific Smad3 phosphorylation patterns among 52 PBC patients with various stages of fibrosis and 25 non-PBC patients with chronic hepatitis C virus infection. HCC developed in 7 of 11 PBC patients showing high pSmad3L immunoreactivity, but in only 2 of 41 PBC patients with low pSmad3L. In contrast, 9 of 20 PBC patients with minimal Smad3C phosphorylation developed HCC, while HCC did not occur during follow-up in 32 patients who retained hepatic tumor-suppressive pSmad3C. Further, PBC patients whose liver specimens showed high pSmad3L positivity were relatively likely to develop HCC even when little fibrosis was evident. | |||||
| 抄録 | ||||||
| 内容記述タイプ | Abstract | |||||
| 内容記述 | In this study, Smad phospho-isoform status showed promise as a biomarker predicting likelihood of HCC occurrence in PBC. Eventually, therapies to shift favorably Smad phospho-isoforms might decrease likelihood of PBC-related HCC. | |||||
| 学位名 | ||||||
| 学位名 | 博士（医学） | |||||
| 学位授与機関 | ||||||
| 学位授与機関名 | 関西医科大学 | |||||
| 学位授与年度 | ||||||
| 内容記述タイプ | Other | |||||
| 内容記述 | 令和三年度 | |||||
| 学位授与年月日 | ||||||
| 学位授与年月日 | 2021-12-23 | |||||
| 学位授与番号 | ||||||
| 学位授与番号 | 課博第1112号 | |||||
| 書誌情報 |
Frontiers in bioscience (Landmark edition) en : Frontiers in bioscience (Landmark edition) 巻 26, 号 12, p. 1480-1492, 発行日 2021-12-30 |
|||||
| DOI | ||||||
| 表示名 | 10.52586/5042 | |||||
| URL | https://doi.org/10.52586/5042 | |||||
